The Benefits of TIMOPTIC® in OCUDOSE®
For patients with glaucoma who are most sensitive to the side effects associated with preservatives in eye drops, TIMOPTIC® in OCUDOSE® offers a preservative-free alternative.
TIMOPTIC® in OCUDOSE® has shown clinical impact beyond IOP reduction.1
TIMOPTIC® in OCUDOSE® does not contain BAK (benzalkonium chloride), which has been shown to adversely affect both the cornea and conjunctiva, thereby leading to ocular damage.2
- Using preservative-free medication may reduce side effects and increase medication tolerability
Ocular Surface Health
TIMOPTIC® in OCUDOSE® maintains tear film stability and tear film breakup time.1
The potential for long-term consequences of ocular surface toxicity is reduced, along with superficial punctate keratitis.1
In a large epidemiological study, compared with preserved eye drops, preservative-free eye drops showed the following advantages3:
- Less frequency of all symptoms
- Less discomfort upon administration of eye drops
- Less frequently reported signs of ocular surface damage
- Fewer instances of mild or severe superficial punctate keratitis
- Less frequency of blepharitis and eczema
- Conjunctival signs were less present
- Patients who were switched from preservative to preservative-free eye drops showed a significant decrease in the frequency of side effects
Unpreserved timolol, found in TIMOPTIC®, has been found to not cause any ocular cell toxicity.4
The benefits of using a preservative-free glaucoma medication like TIMOPTIC® in OCUDOSE® are clear. Speak with your eye care professional today about how TIMOPTIC® in OCUDOSE® can help you effectively treat your glaucoma.
References: 1. Manni G, Centofanti M, Oddone F, Parravano M, Bucci MG. Interleukin-1 βtear concentration in glaucomatod/us and ocular hypertensive patients treated with preservative-free nonselective beta-blockers. Am J Ophthalmol. 2005;139:72-77. 2. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490-496. 3. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002;86:418-423. 4. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004;45:1360 –1368.
